Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Typ-2-Diabetes und Adipositas Klimawandel und Gesundheit Neues aus dem Markt Praxis und Beruf Seltene Erkrankungen GOÄ & EBM
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Fachpsychotherapie Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende Patientenratgeber
Erweiterte Suche
Anmelden
nach oben
Current Treatment Options in Pediatrics
Erschienen in:

01.12.2023 | Pediatric Infectious Disease (M Mitchell and F Zhu, Section Editors)

Updates in the Approach to Pediatric HIV Care and Prevention

verfasst von: Claudia Vicetti Miguel, MD, Sheryl L. Henderson, MD, PhD

Erschienen in: Current Treatment Options in Pediatrics | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Purpose of review

Awareness of updates on the recommendations for the treatment and prevention of HIV in children and adolescents is of vital importance for pediatricians to support HIV elimination efforts in the USA.

Recent findings

Children with HIV infection have access to potent antiretroviral regimens in combined and easier to administer formulations. For youth with HIV, simpler and long-acting treatment regimens are available. For infants born to persons with HIV that have low risk of perinatal transmission, an abbreviated regimen is recommended. Breastfeeding is supported for individuals on HIV treatment who remain virally suppressed. For adolescents and young adults at significant risk of HIV, pre-exposure prophylaxis is recommended.

Summary

Early treatment remains paramount for best outcomes in children and adolescents living with HIV, aided by innovative drugs and delivery methods. These advances should strive to equally benefit both the pediatric and adult populations. Despite progress, youth still comprise a significant portion of new HIV cases. Inclusive prevention strategies led by pediatricians are essential for HIV elimination in adolescents and young adults.
Literatur
1.
Antiretroviral Therapy Cohort, C. Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies. Lancet HIV. 2017;4(8):e349–56.CrossRef
2.
• Edwards JK, Cole SR, Breger TL, et al. Mortality among persons entering HIV care compared with the general U.S. population : an observational study. Ann Intern Med. 2021;174(9):1197–206. A comparison of 5-year all-cause mortality rates of adults entering HIV care compared to a matched US population showed that there was an 11% difference in mortality between 1999 and 2004 and that difference decreased to 2.7% between 2011 and 2017, likely reflecting advances in HIV care and treatment.PubMedPubMedCentralCrossRef
3.
Van Dyke RB, Patel K, Siberry GK, et al. Antiretroviral treatment of US children with perinatally acquired HIV infection: temporal changes in therapy between 1991 and 2009 and predictors of immunologic and virologic outcomes. J Acquir Immune Defic Syndr. 2011;57(2):165–73.PubMedPubMedCentralCrossRef
4.
European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group in EuroCoord, Judd A, et al. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: a cohort study. PLoS Med. 2018;15(1):e1002491.CrossRef
5.
Garcia F, de Lazzari E, Plana M, et al. Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr. 2004;36(2):702–13.PubMedCrossRef
6.
Strategies for Management of Antiretroviral Therapy Study G, El-Sadr WM, Lundgren J, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.CrossRef
7.
Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–22.PubMedCrossRef
8.
Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373(9):795–807.PubMedCrossRef
9.
10.
Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5(8):e438–47.PubMedCrossRef
11.
Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. JAMA. 2016;316(2):171–81.PubMedCrossRef
12.
Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393(10189):2428–38.PubMedPubMedCentralCrossRef
13.
Tubiana R, Le Chenadec J, Rouzioux C, et al. Factors associated with mother-to-child transmission of HIV-1 despite a maternal viral load <500 copies/ml at delivery: a case-control study nested in the French perinatal cohort (EPF-ANRS CO1). Clin Infect Dis. 2010;50(4):585–96.PubMedCrossRef
14.
Townsend CL, Cortina-Borja M, Peckham CS, et al. Low rates of mother-to-child transmission of HIV following effective pregnancy interventions in the United Kingdom and Ireland, 2000-2006. AIDS. 2008;22(8):973–81.PubMedCrossRef
15.
Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med. 2008;359(21):2233–44.PubMedPubMedCentralCrossRef
16.
Shiau S, Arpadi S, Strehlau R, et al. Initiation of antiretroviral therapy before 6 months of age is associated with faster growth recovery in South African children perinatally infected with human immunodeficiency virus. J Pediatr. 2013;162(6):1138–45. 1145 e1-2PubMedPubMedCentralCrossRef
17.
Jantarabenjakul W, Chonchaiya W, Puthanakit T, et al. Low risk of neurodevelopmental impairment among perinatally acquired HIV-infected preschool children who received early antiretroviral treatment in Thailand. J Int AIDS Soc. 2019;22(4):e25278.PubMedPubMedCentralCrossRef
18.
• Massanella M, Puthanakit T, Leyre L, et al. Continuous prophylactic antiretrovirals/antiretroviral therapy since birth reduces seeding and persistence of the viral reservoir in children vertically infected with human immunodeficiency virus. Clin Infect Dis. 2021;73(3):427–38. This study measured levels of HIV DNA and frequencies of cells producing multiply spliced RNA after stimulation in infants with perinatally-acquired HIV and noted that both were significantly lower in infants who received ARV prophylaxis and directly transitioned to ART after HIV diagnosis compared to infants who discontinued or never initiated ARV prophylaxis prior to ART.PubMedCrossRef
19.
Collaborative Initiative for Paediatric HIV Education and Research (CIPHER) Global Cohort Collaboration, Slogrove AL, et al. The epidemiology of adolescents living with perinatally acquired HIV: a cross-region global cohort analysis. PLoS Med. 2018;15(3):e1002514.CrossRef
20.
21.
Nielsen-Saines K, Watts DH, Veloso VG, et al. Three postpartum antiretroviral regimens to prevent intrapartum HIV infection. N Engl J Med. 2012;366(25):2368–79.PubMedPubMedCentralCrossRef
22.
Neubert J, Pfeffer M, Borkhardt A, et al. Risk adapted transmission prophylaxis to prevent vertical HIV-1 transmission: effectiveness and safety of an abbreviated regimen of postnatal oral zidovudine. BMC Pregnancy Childbirth. 2013;13:22.PubMedPubMedCentralCrossRef
23.
Nguyen TTT, Kobbe R, Schulze-Sturm U, et al. Reducing hematologic toxicity with short course postexposure prophylaxis with zidovudine for HIV-1 exposed infants with low transmission risk. Pediatr Infect Dis J. 2019;38(7):727–30.PubMedCrossRef
24.
25.
26.
•• Lampe MA, Nesheim SR, Oladapo KL, Ewing AC, Wiener J, Kourtis AP. Achieving Elimination of perinatal HIV in the United States. Pediatrics. 2023;151(5):e2022059604. This study demonstrated that the diagnosis rates declined from 1.9 to 0.9 per 100 000 live births and the transmission rates from 1.6 to 0.9% achieving perinatal HIV elimination goals in 2019.
27.
Nesheim S, Taylor A, Lampe MA, et al. A framework for elimination of perinatal transmission of HIV in the United States. Pediatrics. 2012;130(4):738–44.PubMedCrossRef
28.
29.
von Hentig N. Clinical use of cobicistat as a pharmacoenhancer of human immunodeficiency virus therapy. HIV AIDS (Auckl). 2016;8:1–16.
30.
31.
Faye A, Le Chenadec J, Dollfus C, et al. Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis. 2004;39(11):1692–8.PubMedCrossRef
32.
Luzuriaga K. Early combination antiretroviral therapy limits HIV-1 persistence in Children. Annu Rev Med. 2016;67:201–13.PubMedCrossRef
33.
Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol. 2000;74(15):6984–91.PubMedPubMedCentralCrossRef
34.
Bitnun A, Samson L, Chun TW, et al. Early initiation of combination antiretroviral therapy in HIV-1-infected newborns can achieve sustained virologic suppression with low frequency of CD4+ T cells carrying HIV in peripheral blood. Clin Infect Dis. 2014;59(7):1012–9.PubMedPubMedCentralCrossRef
35.
Kariyawasam D, Peries M, Foissac F, et al. Lopinavir-ritonavir impairs adrenal function in infants. Clin Infect Dis. 2020;71(4):1030–9.PubMedCrossRef
36.
Simon A, Warszawski J, Kariyawasam D, et al. Association of prenatal and postnatal exposure to lopinavir-ritonavir and adrenal dysfunction among uninfected infants of HIV-infected mothers. JAMA. 2011;306(1):70–8.PubMedCrossRef
37.
38.
McArthur MA, Kalu SU, Foulks AR, et al. Twin preterm neonates with cardiac toxicity related to lopinavir/ritonavir therapy. Pediatr Infect Dis J. 2009;28(12):1127–9.PubMedCrossRef
39.
Bekker A, Decloedt EH, Slade G, et al. Single dose abacavir pharmacokinetics and safety in neonates exposed to human immunodeficiency virus (HIV). Clin Infect Dis. 2021;72(11):2032–4.PubMedCrossRef
40.
Bekker A, Capparelli EV, Violari A, et al. Abacavir dosing in neonates from birth to 3 months of life: a population pharmacokinetic modelling and simulation study. Lancet HIV. 2022;9(1):e24–31.PubMedCrossRef
41.
World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021. p. 594.
42.
• Panel on Treatment of HIV During Pregnancy and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs during pregnancy and interventions to reduce perinatal HIV Transmission in the United States. Department of Health and Human Services. https://​clinicalinfo.​hiv.​gov/​sites/​default/​files/​guidelines/​documents/​perinatal-hiv/​guidelines-perinatal.​pdf. Accessed 23 Aug 2023. The January 2023 updates to the guidelines contain significant changes to their infant feeding recommendations to support birthing parents who wish to breast/chestfeed after decades of discouraging this practice. The document summarizes the evidence that breastfeeding can be performed safely under specific circumstances and with ongoing support by providers. Though not zero, the risk of postnatal HIV transmission through breast milk can be <1%.
43.
de Waal R, Rabie H, Technau KG, et al. Abacavir safety and effectiveness in young infants with HIV in South African observational cohorts. Antivir Ther. 2023;28(2):13596535231168480.PubMed
44.
Clarke DF, Mirochnick M, Acosta E, et al. Use of modeling and simulations to determine raltegravir dosing in neonates: a model for safely and efficiently determining appropriate neonatal dosing regimens: IMPAACT P1110. J Acquir Immune Defic Syndr. 2019;82(4):392–8.PubMedPubMedCentralCrossRef
45.
Clarke DF, Acosta E, Cababasay M, et al. Raltegravir (RAL) in neonates: dosing, pharmacokinetics (PK), and safety in HIV-1-exposed neonates at risk of infection (IMPAACT P1110). J Acquir Immune Defic Syndr. 2020;84(1):70–7.PubMedPubMedCentralCrossRef
46.
Witvrouw M, Pannecouque C, Switzer WM, et al. Susceptibility of HIV-2, SIV and SHIV to various anti-HIV-1 compounds: implications for treatment and postexposure prophylaxis. Antivir Ther. 2004;9(1):57–65.PubMedCrossRef
47.
48.
Ruel TD, Acosta E, Liu J, et al. Pharmacokinetics, safety, tolerability, and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1 (IMPAACT P1093): results of an open-label, phase 1-2 trial. Lancet HIV. 2022;9(5):e332–40.PubMedPubMedCentralCrossRef
49.
50.
51.
52.
Gilead Sciences. A phase 2/3, open-label study of the pharmacokinetics, safety, and antiviral activity of the elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) Single Tablet (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children. 2023. https://​clinicaltrials.​gov/​study/​NCT01854775. (Identification No NCT01854775). Accessed 25 Aug 2023.
53.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331(18):1173–80.PubMedCrossRef
54.
Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339(20):1409–14.PubMedCrossRef
55.
Myer L, Phillips TK, McIntyre JA, et al. HIV viraemia and mother-to-child transmission risk after antiretroviral therapy initiation in pregnancy in Cape Town, South Africa. HIV Med. 2017;18(2):80–8.PubMedCrossRef
56.
Mandelbrot L, Tubiana R, Le Chenadec J, et al. No perinatal HIV-1 transmission from women with effective antiretroviral therapy starting before conception. Clin Infect Dis. 2015;61(11):1715–25.PubMed
57.
Townsend CL, Byrne L, Cortina-Borja M, et al. Earlier initiation of ART and further decline in mother-to-child HIV transmission rates, 2000-2011. AIDS. 2014;28(7):1049–57.PubMedCrossRef
58.
Boucher FD, Modlin JF, Weller S, et al. Phase I evaluation of zidovudine administered to infants exposed at birth to the human immunodeficiency virus. J Pediatr. 1993;122(1):137–44.PubMedCrossRef
59.
Taha TE, Kumwenda NI, Hoover DR, et al. The impact of breastfeeding on the health of HIV-positive mothers and their children in sub-Saharan Africa. Bull World Health Organ. 2006;84(7):546–54.PubMedPubMedCentralCrossRef
60.
World Health Organization. United Nations Children’s Fund. Guideline: updates on HIV and infant feeding: the duration of breastfeeding, support from health services to improve feeding practices among mothers living with HIV. Geneva: World Health Organization; 2016.
61.
Flynn PM, Taha TE, Cababasay M, et al. Prevention of HIV-1 transmission through breastfeeding: efficacy and safety of maternal antiretroviral therapy versus infant nevirapine prophylaxis for duration of breastfeeding in HIV-1-infected women with high CD4 cell count (IMPAACT PROMISE): a randomized, open-label, clinical trial. J Acquir Immune Defic Syndr. 2018;77(4):383–92.PubMedPubMedCentralCrossRef
62.
Yusuf HE, Knott-Grasso MA, Anderson J, et al. Experience and outcomes of breastfed infants of women living with HIV in the United States: findings from a single-center breastfeeding support initiative. J Pediatric Infect Dis Soc. 2022;11(1):24–7.PubMedCrossRef
63.
Weiss F, von Both U, Rack-Hoch A, et al. Brief report: HIV-positive and breastfeeding in high-income settings: 5-year experience from a perinatal center in Germany. J Acquir Immune Defic Syndr. 2022;91(4):364–7.PubMedCrossRef
64.
Nashid N, Khan S, Loutfy M, et al. Breastfeeding by women living with human immunodeficiency virus in a resource-rich setting: a case series of maternal and infant management and outcomes. J Pediatric Infect Dis Soc. 2020;9(2):228–31.PubMedCrossRef
65.
Koay WLA, Rakhmanina NY. Supporting mothers living with HIV in the United States who choose to breastfeed. J Pediatric Infect Dis Soc. 2022;11(5):239.PubMedCrossRef
66.
Prestileo T, Adriana S, Lorenza DM, Argo A. From undetectable equals untransmittable (U=U) to breastfeeding: Is the Jump Short? Infect Dis Rep. 2022;14(2):220–7.PubMedPubMedCentralCrossRef
67.
••Levison, J., J. McKinney, A. Duque, et al., Breastfeeding among people with HIV in North America: a multisite study. Clin Infect Dis. 2023;ciad235. This multi-site retrospective study from 11 sites in the USA and Canada of 72 individuals with HIV who were on ART and breastfed their infants showed that no cases of infant HIV transmission occurred among the 94% of infants for whom HIV testing results were available at least 6 weeks after weaning.
68.
Wood SM, Dowshen N, Lowenthal E. Time to improve the global human immunodeficiency virus/AIDS care continuum for adolescents: a generation at stake. JAMA Pediatr. 2015;169(7):619–20.PubMedPubMedCentralCrossRef
69.
Griffith DC, Farmer C, Gebo KA, et al. Uptake and virological outcomes of single- versus multi-tablet antiretroviral regimens among treatment-naive youth in the HIV Research Network. HIV Med. 2019;20(2):169–74.PubMedCrossRef
70.
Molina JM, Clotet B, van Lunzen J, et al. Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. Lancet HIV. 2015;2(4):e127–36.PubMedCrossRef
71.
Squires K, Kityo C, Hodder S, et al. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomised, controlled, double-blind, phase 3 study. Lancet HIV. 2016;3(9):e410–20.PubMedPubMedCentralCrossRef
72.
Cahn P, Madero JS, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83(3):310–8.PubMedCrossRef
73.
Cahn P, Madero JS, Arribas JR, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–55.PubMedCrossRef
74.
Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase 3 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6(9):e576–87.PubMedCrossRef
75.
Weld ED, Rana MS, Dallas RH, et al. Interest of youth living with HIV in long-acting Antiretrovirals. J Acquir Immune Defic Syndr. 2019;80(2):190–7.PubMedPubMedCentralCrossRef
76.
Flexner C, Owen A, Siccardi M, Swindells S. Long-acting drugs and formulations for the treatment and prevention of HIV infection. Int J Antimicrob Agents. 2021;57(1):106220.PubMedCrossRef
77.
Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390(10101):1499–510.PubMedCrossRef
78.
•• Orkin C, Arasteh K, Gorgolas Hernandez-Mora M, et al. Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection. N Engl J Med. 2020;382(12):1124–35. This randomized open label trial compared adults with HIV who achieved viral suppression after 20 weeks of ABC/3TC/DTG and randomized them to continue oral therapy or switch to CAB+RPV oral for one month followed by monthly injections LA CAB + RPV. This study demonstrated that LA CAB + RPV was non inferior that ABC/3TC/DTG in maintaining HIV suppression.PubMedCrossRef
79.
Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression. N Engl J Med. 2020;382(12):1112–23.PubMedCrossRef
80.
81.
82.
83.
• Parker B, Ward T, Hayward O, et al. Cost-effectiveness of the long-acting regimen cabotegravir plus rilpivirine for the treatment of HIV-1 and its potential impact on adherence and viral transmission: a modelling study. PLoS One. 2021;16(2):e0245955. Peforming parameterisation of pooled data from CAB+RPV trials, CAB+RPV was predicted to be more cost-saving and generating more life-year gains than oral ART, demonstrating the impact of improved adherence on heath and economic outcomes.PubMedPubMedCentralCrossRef
84.
• Centers for Disease Control and Prevention. Preexposure prophylaxis for the prevention of HIV infection in the United States - 2021 Update clinical practice guideline. CDC. 2021.https://​www.​cdc.​gov/​hiv/​pdf/​risk/​prep/​cdc-hiv-prep-guidelines-2021.​pdf. Accessed 11 Jul 2023. The PrEP Guidelines were updated in 2021 to include the recommendation to offer PrEP to any sexually active adolescent with a history of a bacterial STI, inconsistent condom use or a partner with known HIV infection.
85.
Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363(27):2587–99.PubMedPubMedCentralCrossRef
86.
Baeten JM, Donnell D, Ndase, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367(5):399–410.PubMedPubMedCentralCrossRef
87.
Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367(5):423–34.PubMedCrossRef
88.
Choopanya K, Martin M, Suntharasamai, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2013;381(9883):2083–90.PubMedCrossRef
89.
Hosek SG, Landovitz RJ, Kapogiannis B, et al. Safety and feasibility of antiretroviral preexposure prophylaxis for adolescent men who have sex with men aged 15 to 17 years in the United States. JAMA Pediatr. 2017;171(11):1063–71.PubMedPubMedCentralCrossRef
90.
Molina JM, Capitant C, Spire B, et al. On-demand preexposure prophylaxis in men at high risk for HIV-1 infection. N Engl J Med. 2015;373(23):2237–46.PubMedCrossRef
91.
Molina JM, Charreau I, Spire B, et al. Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study. Lancet HIV. 2017;4(9):e402–10.PubMedCrossRef
92.
93.
•• Mayer KH, Molina JM, Thompson MA, et al. Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet. 2020;396(10246):239–54. 5857 cisgender men who have sex with me or transgender women who have sex with men were randomyly assigned to receive either daily FTC/TDF or FTC/TAF for PrEFTC/TAF was shown to be non-inferior that FTC/TDF for HIV prevention.PubMedPubMedCentralCrossRef
94.
•• Landovitz RJ, Donnell D, Clement ME, et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med. 2021;385(7):595–608. 4566 cisgender men who have sex with men and transgender women who have sex with men and who were at-risk for HIV were randomized to receive either TDF/FTC or LA injectable CAB for PrEThe trial was stopped early for efficacy during the first interim end-point analysis that showed 3 times as many incident HIV infections in the TDF/FTC arm. LA CAB was superior to TDF/FTC in preventing HIV.PubMedPubMedCentralCrossRef
95.
•• Delany-Moretlwe S, Hughes J, Bock P, et al. Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial. Lancet. 2022;399(10337):1779–89. This phase 3 clinical trial enrolled 3224 individuals assigned female at birth at risk of HIV, who were randomly assigned to receive either TDF/FTC or LA CAB for PrEIncident HIV infection was 9 times higher in the TDF/FTC group, demonstrating superiority of LA CAB in preventing HIV infection in women.PubMedPubMedCentralCrossRef
96.
Landovitz RJ, Li S, Eron JJ Jr, et al. Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. Lancet HIV. 2020;7(7):e472–81.PubMedPubMedCentralCrossRef
97.
Metadaten
Titel
Updates in the Approach to Pediatric HIV Care and Prevention
verfasst von
Claudia Vicetti Miguel, MD
Sheryl L. Henderson, MD, PhD
Publikationsdatum
01.12.2023
Verlag
Springer International Publishing
Erschienen in
Current Treatment Options in Pediatrics / Ausgabe 4/2023
Elektronische ISSN: 2198-6088
DOI
https://doi.org/10.1007/s40746-023-00278-x

Weitere Artikel der Ausgabe 4/2023

Medication-Induced Kidney Injury for the Primary Care Pediatrician

  • Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

Vomiting in Children: Clinical Scenarios

  • Pediatric Gastroenterology (S Saeed and E Mezoff, Section Editors)

Intrauterine Drug Exposure—What the Pediatrician Needs to Know. Part 1: General Overview, Transplacental Drug Transfer, Teratogenicity, and Fetal Alcohol Spectrum Disorder

  • Pediatric Neonatology (T Thorkelsson, Section Editor)

Social Determinants of Health and Health Equity in Pediatric Cardiology Outcomes

  • Cardiology/CT Surgery (K Gist, Section Editor)

Kidney Manifestations of Rheumatological Diseases in Children

  • Open Access
  • Pediatric Nephrology (BP Dixon and E Nehus, Section Editors)

Updates in Eosinophilic Esophagitis

  • Pediatric Gastroenterology (SA Saeed and E Mezoff, Section Editors)

Kompaktes Leitlinien-Wissen Pädiatrie (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Kostenlos registrieren

Neu im Fachgebiet Pädiatrie

Weniger Bargeld, weniger Erstickungsnotfälle?

Dadurch, dass immer seltener mit Bargeld gezahlt wird, könnte die Rate an Erstickungsnotfällen bei Kindern zurückgehen. Dieser Hypothese ist ein britisches Forschungsteam in Klinikdaten aus den letzten zweieinhalb Jahrzehnten nachgegangen.

Pneumonie ausschließen: Auf das Röntgenbild ist offenbar Verlass

Das Thoraxröntgen ist gemäß Daten aus den USA eine zuverlässige Methode, um bei Kindern in der Notaufnahme rasch eine Lungenentzündung auszuschließen. Zur Vorsicht rät das Ärzteteam jedoch bei bestimmten klinischen Symptomen.

Kawasaki-Syndrom: Kein ASS mehr in der Akutphase?

Um Kinder mit Kawasaki-Syndrom vor entzündlich bedingten Veränderungen der Koronarien zu bewahren, werden sie in der Akutphase mit intravenösen Immunglobulinen und hochdosierter Acetylsalicylsäure (ASS) behandelt. Neuesten Daten zufolge könnte womöglich auf ASS verzichtet werden.

Neurologische Entwicklung von Kindern: Welchen Einfluss hat Stillen?

Stillen bringt zahlreiche gesundheitliche Vorteile mit sich. Ob dazu auch ein niedrigeres Risiko für Entwicklungsverzögerungen und -störungen gehört, hat nun eine israelische Studie untersucht.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise